High-Grade Pneumonitis Events in Patients With Unresectable, Locally Advanced NSCLC Treated With Definitive Chemoradiation Followed by Adjuvant Durvalumab

High-Grade Pneumonitis Events in Patients With Unresectable, Locally Advanced NSCLC Treated With Definitive Chemoradiation Followed by Adjuvant Durvalumab

Background: The standard of care for unresectable locally advanced NSCLC is concurrent chemotherapy and radiation (CRT) followed by adjuvant durvalumab, established by the PACIFIC trial, which revealed acceptable although higher rates of pneumonitis with durvaluamb than placebo. We retrospectively r...

Full description

Saved in:
Bibliographic Details
Main Authors: Ciani Ellison, MD, Michael Martens, PhD, Juliana Alvarez Argote, MD, Samantha Benz, MD, Adam Currey, MD, Candice Johnstone, MD, MPH, Slade Klawikowski, PhD, Katie Livingston, MD, John M. Longo, MD, Smitha Menon, MD, Saryleine Ortiz de Choudens, MD, Lindsay Puckett, MD, Janet Retseck, MD, PhD, Monica Shukla, MD, Jonathan Thompson, MS, MD, Elizabeth Gore, MD, FACR
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:JTO Clinical and Research Reports
Subjects:
Durvalumab
Radiation therapy
Pneumonitis
Locally advanced non–small cell lung
cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364323000772
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items